Franklin Biotechnology Discovery is overseen by experienced managers, but limited resources and an undifferentiated process earn the fund a Morningstar Analyst Rating of Neutral.
- NAV / 1-Day Return 112.43 / 0.36 %
- Total Assets 833.5 Mil
-
Adj. Expense Ratio
- Expense Ratio 1.040%
- Distribution Fee Level Low
- Share Class Type Front Load
- Category Health
- Investment Style Mid Growth
- Min. Initial Investment 1,000
- Status Open
- TTM Yield 0.13%
- Turnover 26%
Morningstar’s Analysis FBDIX
Will FBDIX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.